Tag: R3 Vascular
R3 Vascular announces first patient treated in ELITE-BTK pivotal trial
R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis (New York-Presbyterian and Weill Cornell...
R3 Vascular secures WCG IRB approval and CMS category B Medicare...
R3 Vascular today announced that it has received WCG Institutional Review Board (IRB) approval for the ELITE-BTK pivotal trial of its Magnitude drug-eluting next-generation...
US FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial...
R3 Vascular today announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal...
R3 Vascular reports the initiation of its first-in-human clinical study
R3 Vascular has reported the successful initiation of its first-in-human clinical study evaluating the technical and clinical performance of the R3 Vascular Magnitude bioresorbable...
